Argenta Discovery has entered into an alliance with NeuroSolutions to gain preferential access to its specialist electrophysiology and hERG testing services and expertise.
The collaboration will enable Argenta to provide its contract research clients with an expanded assay development and screening resource; either as part of an integrated drug discovery programme, or as a stand-alone service.
Christopher Ashton, chief executive officer of Argenta Discovery, said: "Argenta has been looking at ways of enhancing its biochemistry and in vitro screening capabilities.
"We have entered into this collaboration with NeuroSolutions to provide Argenta with dedicated access to specialist electrophysiology and hERG screening services, offered by a leader in the field.
"Argenta has a number of contract research programmes in the pipeline for 2008 which will benefit from NeuroSolutions's support and expertise.
"This alliance will enable Argenta to provide assay development and compound screening services across an even wider range of small molecule gene families.
"We are looking forward to working with NeuroSolutions".
Edward Stevens of NeuroSolutions added: "We are pleased to have entered into an alliance with Argenta Discovery.
"It has a well-earned reputation as a quality contract drug discovery service provider to the global pharmaceutical industry.
"NeuroSolutions is a recognised specialist in the electrophysiology and hERG screening fields, and our management team has over 30 years experience in the pharmaceutical and biotechnology sectors.
"This puts NeuroSolutions in a unique position to understand our clients' electrophysiological research needs, and fulfil their expectations".
"We are looking forward to assisting Argenta's contract research clients accelerate their drug discovery programmes."
